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Loss to Follow-up after ART
Initiation
The global HIV epidemic has been
described as a public health emergency,
which is both accurate and misleading. It is
accurate because despite years of coordi-
nated efforts, millions of people worldwide
remain in urgent need of antiretroviral
therapy(ART) [1]. Butthe termemergency
is also misleading because it implies an
acuity that, like a flood or famine, can be
expected to abate once appropriate relief
measures are delivered. Of course, the HIV
pandemic is decades old, HIV care is life-
long, and the HIV-infected population is
young; the end of this public health
emergency is nowhere in sight.
Tracking the progress of early ART
scale-up efforts initially focused on tallying
the number of individuals in need that
actually started ART. A number of reports
from Africa and other settings document-
ed excellent early ART response rates,
even in the face of severe resource
constraints [2–4]. However, many of these
reports also told another story. The
introduction of AIDS care in many sites
has represented a monumental shift in the
way medical care is delivered—from a
model of episodic treatment of symptom-
atic individuals with, for example, malaria,
to one of life-long, chronic care. As such,
the issue of patient attrition, never partic-
ularly considered or measured previously,
emerged as a major issue. In a 2007
systematic review of patient retention in
ART programs in sub-Saharan Africa,
Rosen et al. found that only about 62% of
those started on ART remained in care at
24 months after initiation [5]. Moreover,
loss to follow-up (LTFU), a term used to
describe patients who fail to present to
clinic for a certain period of time and are
not known to have died, accounted for
most of the attrition.
Interruptions in ART are a problem
from a patient care perspective because of
the associated risk of incomplete virologic
suppression [6], ongoing HIV transmis-
sion [7], inflammatory events, immuno-
logic decline, opportunistic infections, and
death [8]. LTFU is also particularly
problematic from the standpoint of clinic
efficiency because attempting to locate
these patients after they become ‘‘late’’ to
clinic is resource-intense and often unsuc-
cessful. In Zambia’s large national treat-
ment program, for example, only one-
third of patients who were late could be
contacted, often after multiple attempts
[9]. Finally, LTFU may lead not only to
overly optimistic estimates of program
response rates but to biased risk factors
for death after ART initiation as well [10].
A Cost-Effectiveness Study from
Co ˆte d’Ivoire
In the current issue of PLoS Medicine,
Losina et al. show the dramatic contribu-
tion of LTFU to overall program effec-
tiveness and cost-effectiveness of a public-
sector program in Co ˆte d’Ivoire [11].
Although data on the efficacy of interven-
tions to reduce LTFU in African settings
are scarce, hypothetical interventions can
be created and their costs estimated. This
approach has allowed Losina and col-
leagues to perform a series of threshold
analyses, where interventions of known
cost are evaluated over a range of
effectiveness estimates. The resultant
range of incremental cost-effectiveness
ratios are plotted against consensus esti-
mates of what the Ivoirian health sector
would be willing to pay.
The authors used real-world cost and
patient outcomes data from ACONDA, a
local nongovernmental organization sup-
porting ART delivery in Co ˆte d’Ivoire to
inform the well-validated Cost-Effective-
ness of Preventing AIDS Complications
(CEPAC) International simulation model.
They evaluated the cost effectiveness of
four hypothetical interventions to reduce
LTFU, which included: (1) removing user
co-payments from antiretroviral and (2)
opportunistic infection drugs, (3) training
providers in methods to improve patient
retention, and (4) provision of meals and
transport reimbursement for patient fol-
low-up visits. The interventions were
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Linked Research Article
This Perspective discusses the fol-
lowing new study published in PLoS
Medicine:
Losina E, Toure ´ H, Uhler LM, Anglaret
X, Paltiel D, et al. (2009) Cost-
effectiveness of Preventing Loss to
Follow-up in HIV Treatment Pro-
grams: a Co ˆte d’Ivoire Appraisal.
PLoS Med 6(10): e1000173. doi:10.
1371/journal.pmed.1000173
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tally (e.g., number 4 was not implemented
without number 3.)
Among the most interesting findings of
the analysis is its base case estimate of the
contribution of LTFU to overall reduc-
tions in program effectiveness. In the
6,703-patient ACONDA-supported pro-
gram, for instance, the authors estimate
that LTFU results in more than 11,000
patient-years of lost life. It is in the context
of this background that these hypothetical
patient-retention interventions must be
considered. For instance, removing user
co-payment from the cost of antiretroviral
drugs, an intervention estimated to cost
$22 per patient per year, would only have
to result in a 12% improvement in LTFU
in order to meet the authors’ criteria for
cost-effectiveness in Co ˆte d’Ivoire. On the
other side of the spectrum, a combination
of all four hypothetical interventions,
estimated to cost $77 per patient per year,
would need to be 41% effective to reach
the cost-effectiveness threshold.
The reported estimates were most
sensitive to modeled costs of second-line
ART (which in Co ˆte d’Ivoire contains
much more expensive protease-inhibitor
drugs). And while programs with the
greatest LTFU rates stood the most to
gain from the interventions, sensitivity
analyses indicated that even programs
with more modest loss rates might find
such interventions to be cost-effective.
The Global HIV Emergency:
Acute ART Scale-up and Chronic
HIV Care
Losina and colleagues’ study signals an
important widening of research attention
to include not only the relative excitement
of expanding ART coverage but also the
less glorious work of improving chronic
HIV care. The paper further quantifies
the well-known problem of LTFU and
provides a cost-effectiveness framework
within which policy makers can begin to
consider how to make their ART pro-
grams succeed over the long run. Al-
though the efficacy of interventions to
reduce LTFU remains largely unknown,
this analysis makes clear that even inter-
ventions of modest efficacy are likely to fall
well within the range of accepted cost-
effectiveness. Clinical trials or other com-
parative studies aimed at evaluating such
interventions would seem to be of high
priority.
Given the financial scope of the global
HIV/AIDS response, even small gains in
program efficiencies and cost-effectiveness
could translate into huge savings and, by
extension, new lives saved. For this reason,
the major AIDS donors, such as the US
President’s Emergency Plan For AIDS
Relief (PEPFAR) and the Global Fund,
should be keenly interested in this issue,
and willing to invest in strategies to
improve retention. Individual country
programs also have a huge stake in
minimizing LTFU. Not only do retained
and appropriately treated patients have
better clinical outcomes, they presumably
are much less infectious and capable of
transmitting the virus to others. Thus,
treating and preventing HIV go hand in
hand. Improving retention in HIV/AIDS
care makes clear programmatic sense and,
as Losina and colleagues demonstrate, it
makes economic sense as well.
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